Augustine Therapeutics

Augustine Therapeutics is a Belgian clinical-stage biotech spun out of VIB-KU Leuven that is building a next-generation class of selective HDAC6 inhibitors for chronic diseases. Using a proprietary non-hydroxamate, non-hydrazide chemotype, the company designs molecules that block HDAC6's harmful catalytic activity while sparing its beneficial functions - aiming to avoid the toxicity that stalled earlier inhibitors. Its lead candidate, AGT-100216, is the first selective HDAC6 inhibitor to enter the clinic for Charcot-Marie-Tooth disease, with a pipeline extending into neurodegenerative and cardio-metabolic indications.